METASTATIC COLORECTAL ADENOCARCINOMA
Clinical trials for METASTATIC COLORECTAL ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC COLORECTAL ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC COLORECTAL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to outperform standard care in tough colorectal cancer
Disease control CompletedThis Phase 3 trial tested a new drug combination called MK-4280A (favezelimab plus pembrolizumab) against standard treatments (regorafenib or TAS-102) in 441 people with advanced colorectal cancer that had stopped responding to prior therapy. The goal was to see if the new combin…
Matched conditions: METASTATIC COLORECTAL ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New combo therapy shows promise for Tough-to-Treat colon cancer
Disease control CompletedThis early-phase study tested a combination of two drugs, cabozantinib and TAS-102, in 15 people with advanced colorectal cancer that had spread and stopped responding to standard treatments. The main goal was to find the safest dose and identify side effects. The study is comple…
Matched conditions: METASTATIC COLORECTAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: University of California, Irvine • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New combo therapy shows promise in advanced cancer trial
Disease control CompletedThis early-phase study tested a new drug called gevokizumab alongside standard cancer treatments in 167 adults with advanced colorectal, stomach, or kidney cancer that had spread. The goal was to find a safe and active dose and see if the combination could help control the diseas…
Matched conditions: METASTATIC COLORECTAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New combo therapy shows promise for Tough-to-Treat colorectal cancer
Disease control CompletedThis study tested a combination of two drugs, lenvatinib and pembrolizumab, against the usual treatments for people with advanced colorectal cancer that had spread and stopped responding to prior therapy. About 563 adults took part. The goal was to see if the new combo helped peo…
Matched conditions: METASTATIC COLORECTAL ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New cocktail of drugs shows promise for tough colorectal cancer
Disease control CompletedThis phase 1 trial tested a combination of regorafenib (a targeted therapy) plus two immunotherapy drugs (nivolumab and ipilimumab) in 39 patients with advanced colorectal cancer that had spread and stopped responding to chemotherapy. The goal was to find the safest dose and chec…
Matched conditions: METASTATIC COLORECTAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New hope for tough colorectal cancer? drug combo tested in Late-Stage trial
Disease control CompletedThis phase 3 trial tests a new drug combination, MK-4280A (favezelimab plus pembrolizumab), against standard treatments (regorafenib or TAS-102) in 94 Chinese adults with advanced, PD-L1 positive colorectal cancer that has worsened after prior therapy. The main goal is to see if …
Matched conditions: METASTATIC COLORECTAL ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New cocktail of drugs takes on Hard-to-Treat colon cancer
Disease control CompletedThis study tested combinations of a new drug called etrumadenant (AB928) with other treatments in 227 people whose colorectal cancer had spread. The goal was to see if these combinations could shrink tumors or slow the cancer's growth. Participants received different drug mixes, …
Matched conditions: METASTATIC COLORECTAL ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Arcus Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New combo aims to keep advanced colon cancer in check
Disease control CompletedThis small, early-phase trial tested a combination of two drugs—cetuximab and capecitabine—as a maintenance treatment for people with a specific genetic type of advanced colorectal cancer (KRAS/BRAF wild-type). The main goals were to check safety, find the best dose, and see how …
Matched conditions: METASTATIC COLORECTAL ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 26, 2026 12:59 UTC
-
Blood markers may reveal chemo response in just weeks
Knowledge-focused CompletedThis study looked at 74 people with metastatic colorectal cancer starting their first chemotherapy. Researchers took blood samples early in treatment to measure three markers: CEA, circulating tumor DNA, and total cell-free DNA. The goal was to see if early changes in these marke…
Matched conditions: METASTATIC COLORECTAL ADENOCARCINOMA
Phase: NA • Sponsor: University Hospital, Rouen • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC